Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Short-term Investments (2016 - 2026)

Standard Biotools has reported Short-term Investments over the past 14 years, most recently at $66.7 million for Q4 2025.

  • Quarterly Short-term Investments fell 47.12% to $66.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.7 million through Dec 2025, down 47.12% year-over-year, with the annual reading at $66.7 million for FY2025, 47.12% down from the prior year.
  • Short-term Investments was $66.7 million for Q4 2025 at Standard Biotools, up from $65.5 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $175.2 million in Q1 2024 and troughed at $40.9 million in Q1 2023.
  • The 4-year median for Short-term Investments is $95.8 million (2022), against an average of $100.0 million.
  • Year-over-year, Short-term Investments plummeted 60.63% in 2023 and then soared 328.7% in 2024.
  • A 4-year view of Short-term Investments shows it stood at $84.5 million in 2022, then decreased by 25.2% to $63.2 million in 2023, then soared by 99.63% to $126.1 million in 2024, then plummeted by 47.12% to $66.7 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Short-term Investments are $66.7 million (Q4 2025), $65.5 million (Q3 2025), and $78.5 million (Q2 2025).